Literature DB >> 28407116

Lethal aplastic anemia caused by dual immune checkpoint blockade in metastatic melanoma.

H Helgadottir1, L Kis1, P Ljungman2,3, J Larkin4,5, R Kefford6, P A Ascierto7, J Hansson1, G Masucci1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28407116     DOI： 10.1093/annonc/mdx177

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  13 in total

Review 1.  Immune checkpoint blockade for advanced non-small cell lung cancer: challenging clinical scenarios.

Authors:  Rebecca Tay; Arsela Prelaj; Raffaele Califano
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

Review 2.  Diagnosis and Treatment of Aplastic Anemia.

Authors:  Scott A Peslak; Timothy Olson; Daria V Babushok
Journal:  Curr Treat Options Oncol       Date:  2017-11-16

3.  PD-1 deficiency augments bone marrow failure in a minor-histocompatibility antigen mismatch lymphocyte infusion model.

Authors:  Maile K Hollinger; Valentina Giudice; Nicole A Cummings; Guillermo Rivell; Hansheng Zhang; Sachiko Kajigaya; Keyvan Keyvanfar; Jichun Chen; Xingmin Feng; Neal S Young
Journal:  Exp Hematol       Date:  2018-03-07       Impact factor: 3.084

Review 4.  Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer.

Authors:  Iosune Baraibar; Ignacio Melero; Mariano Ponz-Sarvise; Eduardo Castanon
Journal:  Drug Saf       Date:  2019-02       Impact factor: 5.606

Review 5.  Immune Checkpoint Inhibitor Toxicity.

Authors:  David J Palmieri; Matteo S Carlino
Journal:  Curr Oncol Rep       Date:  2018-07-31       Impact factor: 5.945

6.  Aplastic anemia secondary to nivolumab and ipilimumab in a patient with metastatic melanoma: a case report.

Authors:  D E Meyers; W F Hill; A Suo; V Jimenez-Zepeda; T Cheng; N A Nixon
Journal:  Exp Hematol Oncol       Date:  2018-03-20

Review 7.  Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse events.

Authors:  Esmée P Hoefsmit; Elisa A Rozeman; John B A G Haanen; Christian U Blank
Journal:  ESMO Open       Date:  2019-07-21

8.  Challenges in diagnosis and management of neutropenia upon exposure to immune-checkpoint inhibitors: meta-analysis of a rare immune-related adverse side effect.

Authors:  J Boegeholz; C S Brueggen; C Pauli; F Dimitriou; E Haralambieva; R Dummer; M G Manz; C C Widmer
Journal:  BMC Cancer       Date:  2020-04-14       Impact factor: 4.430

Review 9.  [Clinical Diagnosis and Treatment Recommendations for Immune Checkpoint Inhibitor-related Hematological Adverse Events].

Authors:  Junling Zhuang; Jingting Zhao; Xiaoxiao Guo; Jiaxin Zhou; Lian Duan; Wei Qiu; Xiaoyan Si; Li Zhang; Yue Li; Xiaowei Liu; Hanping Wang; Daobin Zhou; Li Zhang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2019-10-20

10.  Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events.

Authors:  Julie R Brahmer; Hamzah Abu-Sbeih; Paolo Antonio Ascierto; Jill Brufsky; Laura C Cappelli; Frank B Cortazar; David E Gerber; Lamya Hamad; Eric Hansen; Douglas B Johnson; Mario E Lacouture; Gregory A Masters; Jarushka Naidoo; Michele Nanni; Miguel-Angel Perales; Igor Puzanov; Bianca D Santomasso; Satish P Shanbhag; Rajeev Sharma; Dimitra Skondra; Jeffrey A Sosman; Michelle Turner; Marc S Ernstoff
Journal:  J Immunother Cancer       Date:  2021-06       Impact factor: 13.751
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.